Accéder au contenu
Merck

Narrative review: furosemide for hypercalcemia: an unproven yet common practice.

Annals of internal medicine (2008-08-20)
Susan B LeGrand, Dona Leskuski, Ivan Zama
RÉSUMÉ

Although primary hyperparathyroidism is the most common cause of hypercalcemia, cancer is the most common cause requiring inpatient intervention. An estimated 10% to 20% of all patients with cancer have hypercalcemia at some point in their disease trajectory, particularly in advanced disease. Aggressive saline hydration and varying doses of furosemide continue to be the standard of care for emergency management. However, a review of the evidence for the use of furosemide in the medical management of hypercalcemia yields only case reports published before the introduction of bisphosphonates, in contrast to multiple randomized, controlled trials supporting the use of bisphosphonates. The use of furosemide in the management of hypercalcemia should no longer be recommended.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Furosemide
Supelco
Furosemide, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Furosemide, United States Pharmacopeia (USP) Reference Standard
Supelco
Furosemide solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Furosemide, European Pharmacopoeia (EP) Reference Standard
Furosemide for peak identification, European Pharmacopoeia (EP) Reference Standard